Huarui Cui

发表

Selective N-terminal BRD4 bromodomain inhibitors by targeting non-conserved residues and structured water displacement.

A. Pandey, K. Shi, D. Harki, 2020, Angewandte Chemie.

A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes.

V. Shah, K. Shi, D. Harki, 2022, Journal of medicinal chemistry.

Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C‐C Motif Chemokine Ligand 2–Mediated Angiocrine Signaling

V. Shah, P. Hirsova, Jinhang Gao, 2020, Hepatology.

Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis

R. Bataller, V. Shah, Jinhang Gao, 2021, Nature Communications.

Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.

N. Mishra, N. Berndt, D. Harki, 2018, Journal of medicinal chemistry.

Quantifying the Selectivity of Protein-Protein and Small Molecule Interactions with Fluorinated Tandem Bromodomain Reader Proteins.

A. Pandey, J. Hawkinson, J. Solberg, 2020, ACS chemical biology.

Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors.

Jorden A. Johnson, W. Pomerantz, A. Carlson, 2019, ACS medicinal chemistry letters.

From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors.

M. Roussel, J. Klco, Lei Yang, 2023, European journal of medicinal chemistry.

4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity.

G. Miller, K. Shi, D. Harki, 2021, Journal of medicinal chemistry.